Lv61
1960 积分 2023-10-23 加入
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
6天前
已完结
Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
1个月前
已完结
Synthesis and biological evaluation of azobicyclo[3.3.0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes
1个月前
已完结
The Immunosuppressant Cyclosporin A Antagonizes Human Formyl Peptide Receptor through Inhibition of Cognate Ligand Binding
1个月前
已完结
Design, Synthesis, and Evaluation of a Series of Novel Super Long-Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer
1个月前
已完结
182. Seltorexant, Adjunctive to Antidepressants, in Adults With Major Depressive Disorder With Insomnia Symptoms: Results of a Double-Blind, Randomized, Placebo-Controlled Study
2个月前
已完结
An Overview of PROTACs Targeting MDM2 as a Novel Approach for Cancer Therapy
2个月前
已完结
Discovery of MD-265: A Potent MDM2 Degrader That Achieves Complete Tumor Regression and Improves Long-Term Survival of Mice with Leukemia
2个月前
已完结
皖公网安备34019202002308
